Patent classifications
C07D471/02
Crystalline solid forms of a bet inhibitor
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Crystalline solid forms of a bet inhibitor
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
1,4-substituted piperidine derivatives
Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##
1,4-substituted piperidine derivatives
Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##
Chlorinated napthalenetetracarboxylic acid derivatives, preparation thereof and use thereof in organic electronics
The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.
Chlorinated napthalenetetracarboxylic acid derivatives, preparation thereof and use thereof in organic electronics
The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.
Crystalline solid forms of a BET inhibitor
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Crystalline solid forms of a BET inhibitor
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Isoindolinone inhibitors of phosphatidylinositol 3-kinase
- Alex Aronov ,
- Jon H. Come ,
- Robert J. Davies ,
- Albert Charles Pierce ,
- Philip N. Collier ,
- Ronald Lee Grey ,
- Hardwin O'Dowd ,
- James A. Henderson ,
- Elaine B. Krueger ,
- Anne-Laure Grillot ,
- Arnaud Le Tiran ,
- Yusheng LIAO ,
- David Messersmith ,
- Jian Wang ,
- Jingrong Cao ,
- Upul Keerthi BANDARAGE ,
- Suganthini S. Nanthakumar
The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
MODULATORS OF TNF-ALPHA ACTIVITY
Provided herein are inhibitors of TNF-?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-? inhibitory compounds for the treatment of diseases or disorders.